Pages that link to "Q43525122"
Jump to navigation
Jump to search
The following pages link to Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients (Q43525122):
Displaying 50 items.
- Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature (Q26752774) (← links)
- Managing Side Effects of Vemurafenib Therapy for Advanced Melanoma (Q26795510) (← links)
- Nanoparticle-mediated drug delivery for treating melanoma (Q26798379) (← links)
- Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients (Q27853121) (← links)
- Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade (Q28119095) (← links)
- Multikinase Inhibitor-Induced Hand-Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management (Q30250106) (← links)
- Metastatic melanoma: New paradigms of treatment and new toxicities (Q33697326) (← links)
- Localized Epidermal Cysts as a Radiation Recall Phenomenon in a Melanoma Patient Treated with Radiotherapy and the BRAF Inhibitor Vemurafenib (Q34403517) (← links)
- No human virus sequences detected by next-generation sequencing in benign verrucous skin tumors occurring in BRAF-inhibitor-treated patients (Q35013602) (← links)
- Cutaneous epithelial tumors induced by vemurafenib involve the MAPK and Pi3KCA pathways but not HPV nor HPyV viral infection (Q35381501) (← links)
- Contribution of Beta-HPV Infection and UV Damage to Rapid-Onset Cutaneous Squamous Cell Carcinoma during BRAF-Inhibition Therapy (Q35569132) (← links)
- Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment (Q35821826) (← links)
- Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. (Q36078348) (← links)
- Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib (Q36690502) (← links)
- Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. (Q37527772) (← links)
- Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors (Q37690136) (← links)
- BRAF and beyond: Tailoring strategies for the individual melanoma patient (Q37702515) (← links)
- Cutaneous adverse events to type I BRAF inhibitors: an analysis of effects associated with each inhibitor and therapeutic time interval to onset (Q38139282) (← links)
- Mechanism and consequences of RAF kinase activation by small-molecule inhibitors (Q38197024) (← links)
- Managing the skin toxicities from new melanoma drugs (Q38215416) (← links)
- Dermatological toxicity associated with targeted therapies in cancer: optimal management (Q38239381) (← links)
- Molecular markers for thyroid cancer diagnosis, prognosis, and targeted therapy (Q38243095) (← links)
- Perspective of Targeting Cancer-Associated Fibroblasts in Melanoma (Q38549236) (← links)
- Surgical Management of Melanoma (Q38646103) (← links)
- BRAF inhibitor-associated cutaneous squamous cell carcinoma: new mechanistic insight, emerging evidence for viral involvement and perspectives on clinical management (Q38764961) (← links)
- Low-concentration vemurafenib induces the proliferation and invasion of human HaCaT keratinocytes through mitogen-activated protein kinase pathway activation (Q38867037) (← links)
- Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors (Q38948950) (← links)
- Optimal Use of BRAF Targeting Therapy in the Immunotherapy Era. (Q38950577) (← links)
- Drug-induced eruptive melanocytic nevi (Q38985224) (← links)
- Increased skin and mucosal toxicity in the combination of vemurafenib with radiation therapy (Q40203106) (← links)
- Profile of vemurafenib-induced severe skin toxicities (Q40366752) (← links)
- Delayed-onset vemurafenib-induced panniculitis (Q41563403) (← links)
- Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients (Q41817203) (← links)
- Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients (Q42229504) (← links)
- Multiple palpebral syringomas occurring after initiation of BRAF inhibition therapy in a patient with metastatic melanoma. (Q42355105) (← links)
- Risk of subsequent primary tumor development in melanoma patients. (Q44276104) (← links)
- Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib. Two case reports (Q45150448) (← links)
- Darier disease-like hyperkeratotic papules and invasive squamous cell carcinoma in a patient with melanoma treated with dabrafenib. (Q48289802) (← links)
- Cutis verticis gyrata-like skin toxicity during treatment of melanoma patients with the BRAF inhibitor vemurafenib after whole-brain radiotherapy is a consequence of the development of multiple follicular cysts and milia (Q48691033) (← links)
- Cutaneous Drug Reactions in the Elderly (Q51803601) (← links)
- [Cutaneous side effects of anti-tumor therapy with BRAF and MEK inhibitors]. (Q53063698) (← links)
- [Cutaneous side effects of targeted cancer drugs]. (Q53193539) (← links)
- Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations. (Q54263364) (← links)
- Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors. (Q54302909) (← links)
- Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients. (Q54325214) (← links)
- Multiple squamous cell carcinomas following introduction of nilotinib. (Q54327179) (← links)
- Vemurafenib skin phototoxicity is indirectly linked to ultraviolet A minimal erythema dose decrease. (Q54334683) (← links)
- Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption. (Q54378191) (← links)
- Dermoscopic assessment of skin toxicities in patients with melanoma during treatment with vemurafenib. (Q55130346) (← links)
- Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma (Q58547833) (← links)